Currently out of the existing stock ratings of Soumit Roy, 65 are a BUY (80.25%), 1 are a SELL (1.23%), 15 are a HOLD (18.52%).

Soumit Roy

Work Performance Price Targets & Ratings Chart

Analyst Soumit Roy, currently employed at JONESTRADING, carries an average stock price target met ratio of 37.07% that have a potential upside of 31.67% achieved within 134 days.

Soumit Roy’s has documented 144 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EDIT, Editas Medicine at 10-Mar-2026.

Wall Street Analyst Soumit Roy

Analyst best performing recommendations are on CGEM (CULLINAN ONCOLOGY LLC).
The best stock recommendation documented was for CGEM (CULLINAN ONCOLOGY LLC) at 4/16/2024. The price target of $26 was fulfilled within 13 days with a profit of $8.68 (50.12%) receiving and performance score of 38.55.

Average potential price target upside

of $29.65 (83.5%) on INAB (IN8BIO ).
of $10.96 (100.63%) on CGEM (CULLINAN ONCOLOGY LLC).
of $8.88 (43.48%) on ELVN (ENLIVEN THERAPEUTICS).

DCPH Deciphera Pharmaceuticals LLC INFI Infinity Pharmaceuticals AVEO AVEO Pharmaceuticals SAVA Cassava Sciences SBTX Silverback Therapeutics IKT Inhibikase Therapeutics RAIN Rain Therapeutics TCON TRACON Pharmaceuticals MRTX Mirati Ther MNPR Monopar Therapeutics INAB In8bio CGEM Cullinan Oncology LLC DTIL Precision BioSciences JANX Janux Therapeutics APTO Aptose Biosciences ACRV Acrivon Therapeutics, Common Stock CRVO CervoMed BEAM Beam Therapeutics CMRX Chimerix CRIS Curis ONCY Oncolytics Biotech ACET Adicet Bio AVXL Anavex Life Sciences Corp DAWN Day One Biopharmaceuticals ORIC Oric Pharmaceuticals BCAX Bicara Therapeutics Common Stock EDIT Editas Medicine ELVN Enliven Therapeutics LIFE aTyr Pharma

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Bradley Canino (STIFEL)